)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chongqing Zhifei Biological Products Co
Chongqing Zhifei Biological Products Co (300122) investor relations material
Chongqing Zhifei Biological Products Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary26 Oct, 2026
Executive summary
Q3 revenue was ¥2.515B, down 7.40% YoY; net profit attributable to shareholders was ¥125.3M, up 117.36% YoY.
9M revenue was ¥6.539B, down 14.46% YoY; net loss attributable to shareholders narrowed to ¥683.3M from ¥1.328B.
Financial highlights
9M adjusted net loss attributable to shareholders was ¥687.1M, narrowing 49.04% YoY; Q3 adjusted net profit was ¥119.3M, up 116.44% YoY.
9M consolidated net loss was ¥705.0M, versus ¥1.341B a year earlier; operating loss was ¥858.1M.
9M asset impairment line was a positive ¥210.3M, versus negative ¥119.7M in the prior period; inventory impairment provisions decreased.
Key financial ratios and metrics
Basic and diluted EPS were ¥0.0523 for Q3, each up 117.35% YoY; 9M EPS was -¥0.2854, an improvement of 48.55% YoY.
Total assets were ¥27.132B at quarter-end, down 14.46% from year-end; shareholders’ equity was ¥15.157B, down 4.31%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chongqing Zhifei Biological Products Co
- Revenue dropped 18% and net loss widened, but innovation and cash flow improved.300122
Q2 2026 - First annual net loss driven by industry downturn and asset impairment, but liquidity and R&D held firm.300122Q4 2025
- Q1 2026 saw lower revenue, a wider net loss, and a VAT hike set to impact future results.300122Q1 2026
- Revenue and profit plunged year-over-year, with a net loss and improved operating cash flow.300122Q3 2025
- Revenue and profit declined sharply, but R&D and cash flow remained robust.300122Q2 2025
- Revenue and profit plunged amid weak sales, negative cash flow, and rising short-term debt.300122Q3 2024
- H1 2024 revenue and profit declined sharply, but R&D and market leadership continued.300122Q2 2024
- 2024 saw a 50%+ drop in revenue and profit, prompting a strategic focus on R&D and resilience.300122Q4 2024
- Q1 2025 saw a sharp revenue drop and net loss amid weak sales and rising costs.300122Q1 2025
Next Chongqing Zhifei Biological Products Co earnings date
Q4 202623 Apr, 2027
Chongqing Zhifei Biological Products Co
Next Chongqing Zhifei Biological Products Co earnings date
Q4 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chongqing Zhifei Biological Products Co., Ltd. specializes in the research, development, production, and distribution of vaccines and biological products. The company's offerings include vaccines for human use, covering areas such as infectious diseases and immunization programs. In addition to manufacturing, it provides related services and solutions to healthcare institutions and government agencies. The company is headquartered in Chongqing, China, and its shares are listed on the SZSE.